Different Treatment Approaches of Presumed Trematode-Induced Uveitis

February 7, 2024 updated by: Mahmoud Ibrahim, Assiut University
Different Treatment Approaches of Presumed Trematode-Induced Uveitis including periocular injection and medical treatment Nd laser treatment

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Uveitis, characterized by inflammation of the uvea, is a complex and potentially sight-threatening ocular condition that can result from various etiologies. Among causes of uveitis, trematode-induced uveitis represents a distinct and intriguing subset characterized by the presence of a single or multiple pearl like nodules in the anterior chamber (AC) or less commonly in the conjunctive, cornea or even in the ciliary body and posterior segment. Trematodes, or parasitic flatworms, have been implicated in causing uveitis through the migration of larvae or adult worms into the eye, triggering an inflammatory response 1. Despite its rarity, trematode-induced uveitis poses diagnostic and therapeutic challenges due to the diversity of trematode species and the lack of standardized treatment protocols 2. The treatment of trematode-induced uveitis typically involves addressing the underlying parasitic infection and managing the associated inflammation. Various treatment modalities have been reported in literature. Antiparasitic medications have been tried by some authors. Advantages include targeting the underlying cause by killing the parasites. In addition, systemic medications can reach distant sites of infection However, there is no evidence that the parasite is actually living in ocular tissues and the inflammatory process may be directed against already dead parasite 3. Also, they may have side effects. Effectiveness depends on the specific type of trematode and its susceptibility to the chosen medication. Steroid Therapy is considered the gold standard treatment including topical steroids and periocular Injection of Triamcinolone) Advantages: Reduces inflammation in the eye. Provides symptomatic relief. Disadvantages: Does not address the underlying cause (parasitic infection)4. Prolonged or high-dose steroid use may lead to side effects, such as increased intraocular pressure or cataract formation. In resistant cases Surgery has been advocated by many authors Advantages: Surgical removal of nodules may be considered in specific cases. Can be beneficial in cases of severe complications, such as retinal detachment5. Disadvantages: Invasive procedure with associated risks and is mainly aimed at managing complications.

Laser Therapy has been reported to destroy the pearl like nodules using Argon laser Potential damage to surrounding healthy tissue is the main drawback.

Therefore, there is no consensus about the best line of treatment for this entity Rational for this study: Understanding the available treatment options is crucial for healthcare professionals involved in the care of patients with this condition7

Study Type

Interventional

Enrollment (Estimated)

31

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Assiut, Egypt
        • Assiut

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

Clinical Presentation:

Presence of Uveitis: Include patients with clinically diagnosed uveitis, characterized by inflammation of the uvea9.

Suspicion of Trematode Etiology: Include cases where there is a reasonable suspicion or evidence suggesting trematode-induced uveitis based on clinical picture of pearl like whitish AC or subconjunctival nodules characteristic for this specific entity, history of swimming in local ponds and canals in endemic areas.10

Diagnostic Confirmation:

Positive Diagnostic Findings: Include patients with characteristic clinical picture and exclusion of other causes of granulomatous uveitis by appropriate laboratory tests and imaging modalities.11

Severity of Uveitis:

Disease scores at presentation for parasitic granulomatous uveitis Parameter range score Diameter of AC lesion >3mm 1 3-5mm 2 <5mm 3 Grade of AC inflammation +.5 to+1 1

  • 2 to +3 2
  • 4 3 Complications at presentation none 0 Retro corneal scar or corectopia 1 Cataract 2 Glaucomatous optic atrophy 3

Eyes with scores > 5 were started on steroid therapy. Patients with severity scores <= 5at presentation were advised for surgical excision of the AC lesions.

Based on SUN grading scheme for AC cells.

Age and Gender:

All Ages: Consider including patients of all age groups. Both Genders: Include both males and females

Exclusion Criteria:

Alternative Diagnoses:

Presence of Other Ocular Diseases: Exclude patients with other causes of uveitis12.

Concomitant Systemic Infections: Exclude patients with concomitant systemic infections that may independently cause uveitis.

Patients unwilling to participate in the study

Treatment History:

Previous Treatment for Trematode-Induced Uveitis: Exclude patients who have previously undergone treatment specifically for trematode-induced uveitis13.

Non-Compliance: Exclude patients with a history of non-compliance with prescribed treatments.

Contraindications to Specific Treatments:

Contraindications to Medications: Exclude patients with known contraindications to specific antiparasitic medications or corticosteroids.

Ineligibility for Surgery: Exclude patients who are not suitable candidates for surgical interventions14.

Pregnancy and Lactation:

Pregnant or Lactating Women: Consider excluding pregnant or lactating women due to potential risks associated with certain treatments15

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Surgical removal
Surgical removal of the whitish granuloma
Procedure: Surgical removal
Removal of the granuloma
No Intervention: Medical treatment
Topical and systemic steroid
Experimental: Laser treatment
Argon laser
Procedure: Surgical removal
Removal of the granuloma

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Surgical removal
Time Frame: Baseline
Surgical wash of granuloma with topical and systemic steroid
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 21, 2023

Primary Completion (Estimated)

October 21, 2024

Study Completion (Estimated)

December 21, 2024

Study Registration Dates

First Submitted

February 7, 2024

First Submitted That Met QC Criteria

February 7, 2024

First Posted (Estimated)

February 15, 2024

Study Record Updates

Last Update Posted (Estimated)

February 15, 2024

Last Update Submitted That Met QC Criteria

February 7, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Trematode

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Uveitis

Clinical Trials on Surgical removal

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe